| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Desacetyl bisacodyl targets the colon and rectum, evoking increased mucus and chloride secretion. As the active metabolite of bisacodyl and sodium picosulfate, it stimulates intestinal motility and induces laxation. The compound induces epithelial Cl(-) secretion in the colon and rectum. Its mechanism involves stimulation of chloride secretion and increased mucus production, leading to laxative effects. The compound's target is the intestinal epithelium, where it activates secretory pathways.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Desacetyl bisacodyl induces epithelial Cl(-) secretion in rat colon and rectum. The compound evokes several effects at the colon or rectum, including increased mucus and chloride secretion. As the active metabolite of bisacodyl and sodium picosulfate, its activity has been characterized in various in vitro systems. These in vitro findings support its role as a stimulant laxative.
|
| ln Vivo |
In vivo studies have demonstrated that Desacetyl bisacodyl is the active metabolite of bisacodyl and sodium picosulfate, evoking laxative effects at the colon or rectum. The compound induces epithelial Cl(-) secretion and increased mucus production in vivo. Its laxative effects have been characterized in animal models and human studies. The compound is not intended for research use as a therapeutic agent but is studied as a metabolite of approved laxatives.
|
| Enzyme Assay |
In vitro enzyme assays for Desacetyl bisacodyl typically involve testing its effects on epithelial chloride secretion. Ion transport is measured using Ussing chamber techniques with colon or rectum tissue preparations. The compound's purity (≥95%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for Desacetyl bisacodyl involve culturing intestinal epithelial cells to evaluate its effects on chloride secretion. Cells are treated with varying concentrations of the compound and ion transport is measured. Cell viability is assessed using standard assays. The compound's effects on mucus secretion are also evaluated. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Desacetyl bisacodyl have been conducted in rat models. Animals are administered the compound and chloride secretion in the colon and rectum is measured. Parameters assessed include electrolyte transport, mucus secretion, and gastrointestinal motility. The compound's laxative effects are evaluated. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Desacetyl bisacodyl reflect its nature as a small diphenylmethane compound. It has a molecular weight of 277.32 and the molecular formula C18H15NO2. As the active metabolite of bisacodyl and sodium picosulfate, it is formed in the intestine following administration of the parent compounds. The compound has a purity of ≥95%. Complete pharmacokinetic profiling would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Desacetyl bisacodyl has been evaluated in the context of its use as a laxative metabolite. As the active metabolite of approved laxatives, it has an established safety profile for therapeutic use. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use as a standalone agent and is intended for research purposes only.
|
| References |
[1]. Fujita T, et, al. Desacetyl bisacodyl-induced epithelial Cl(-) secretion in rat colon and rectum. Biomed Res. 2016;37(1):13-20.
|
| Additional Infomation |
Deacetylbisacodyl is a stimulant laxative. Its physiological action is achieved by increasing intestinal motility and stimulating the secretion of intestinal fluids/electrolytes.
See also: Bisacodyl (active ingredient); Picosulfate (active ingredient). Desacetyl bisacodyl (CAS# 603-41-8) is also known as 4,4'-(pyridin-2-ylmethylene)diphenol. It has the molecular formula C18H15NO2 and a molecular weight of 277.32. The compound is the active metabolite of the stimulant laxatives bisacodyl and sodium picosulfate. Desacetyl bisacodyl evokes increased mucus and chloride secretion at the colon or rectum. It induces epithelial Cl(-) secretion in rat colon and rectum. The compound has a purity of ≥95%. |
| Molecular Formula |
C18H15NO2
|
|---|---|
| Molecular Weight |
277.32
|
| Exact Mass |
277.11
|
| CAS # |
603-41-8
|
| PubChem CID |
69046
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.244g/cm3
|
| Boiling Point |
462.1ºC at 760 mmHg
|
| Melting Point |
>200ºC (dec.)
|
| Flash Point |
233.3ºC
|
| Index of Refraction |
1.655
|
| LogP |
3.673
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=CC(C(C2C=CC(O)=CC=2)C2=CC=CC=N2)=CC=1
|
| InChi Key |
LJROKJGQSPMTKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H15NO2/c20-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(21)11-7-14/h1-12,18,20-21H
|
| Chemical Name |
4-[(4-hydroxyphenyl)-pyridin-2-ylmethyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6059 mL | 18.0297 mL | 36.0594 mL | |
| 5 mM | 0.7212 mL | 3.6059 mL | 7.2119 mL | |
| 10 mM | 0.3606 mL | 1.8030 mL | 3.6059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
